Watch OTLC. Know when insiders buy.
One email the day a filing lands. Free.
OTLC
Oncotelic Therapeutics, Inc.
0.03
+0.01 +50.00%
USD · close Sep 24
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $13.7MP/E 0.1DIV YIELD —FCF YIELD —REV TTM —NET INCOME $247.5MNET CASH —52W 0.02 – 0.11SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $250K | — | — | −$844K | $388K | +39.7% | 0.00 | −$92K | — | — | Aug 13 |
| Q1 2026 · Mar 31 | — | — | — | −$1.9M | −$2.2M | — | 0.00 | −$342K | — | — | May 14 |
| Q4 2025 · Dec 31derived | — | — | — | −$2.5M | $250.4M | — | 0.59 | −$783K | — | — | Aug 13 |
| Q3 2025 · Sep 30 | — | — | — | −$491K | −$1M | — | 0.00 | −$307K | — | — | Nov 17 |
| Q2 2025 · Jun 30 | — | — | — | −$66K | $278K | — | 0.00 | −$126K | — | — | Aug 13 |
| Q1 2025 · Mar 31 | — | — | — | −$101K | −$299K | — | 0.00 | −$167K | — | — | May 14 |
| Q4 2024 · Dec 31derived | — | — | — | −$31K | −$601K | — | 0.00 | −$104K | — | — | Apr 15 |
| Q3 2024 · Sep 30 | — | — | — | −$3.3M | −$3.3M | −2965.8% | -0.01 | −$143K | — | — | Nov 17 |
| Q2 2024 · Jun 30 | — | — | — | −$97K | −$210K | — | 0.00 | −$262K | — | — | Aug 13 |
| Q1 2024 · Mar 31 | — | — | — | −$167K | −$409K | — | 0.00 | −$231K | — | — | May 15 |
| Q4 2023 · Dec 31derived | $0 | — | — | −$113K | −$736K | — | 0.00 | −$373K | — | — | Apr 15 |
| Q3 2023 · Sep 30 | $70K | — | — | $14K | $115K | — | 0.00 | −$249K | — | — | Nov 19 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$3.2M | $249.3M | — | 0.59 | −$1.4M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$3.6M | −$4.5M | — | -0.01 | −$740K | — | — | — | — |
| FY2023 · to Dec 31 | $70K | — | −$6.6M | −$7.9M | -11290.1% | -0.02 | −$1.3M | — | — | — | — |
| FY2022 · to Dec 31 | — | — | −$9.7M | $5.1M | — | 0.01 | −$1.5M | — | — | — | — |
| FY2021 · to Dec 31 | — | — | −$9.1M | −$9.4M | — | -0.03 | −$4.4M | — | — | — | — |
| FY2020 · to Dec 31 | $1.7M | — | −$7.6M | −$9.5M | -545.9% | -0.11 | −$2.8M | — | — | — | — |
Every number comes from Oncotelic Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.